Intec Pharma Reports Top-Line Phase 3 Trial Results of Accordion Pill-Carbidopa/Levodopa in Advanced Parkinson’s Disease Patients – Yahoo Finance

Related Articles:

• Intec Pharma Reports Top-Line Phase 3 Trial Results of Accordion Pill-Carbidopa/Levodopa in Advanced Parkinson's Disease Patients July 22, 2019 JERUSALEM, July 22, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces top-line data from the Company's pivotal Phase 3 trial (the ACCORDANCE trial) evaluating the safety and efficacy of the Accordion Pill®-Carbidopa/Levodopa (AP-CD/LD)...
• Intec Pharma Reports Top-Line Phase 3 Trial Results of Accordion Pill-Carbidopa/Levodopa in Advanced Parkinson's Disease Patients - BioSpace July 22, 2019 Intec Pharma Reports Top-Line Phase 3 Trial Results of Accordion Pill-Carbidopa/Levodopa in Advanced Parkinson's Disease Patients  BioSpacePublished: Jul 22, 2019. Conference Call to begin at 8:30 am ET. JERUSALEM, July 22, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or ...
• Intec Pharma Reports Last Patient Last Visit in Pivotal Phase 3 Trial of Accordion Pill™ Carbidopa/Levodopa for the Treatment of Advanced Parkinson's Disease Patients - Yahoo Finance April 30, 2019 Intec Pharma Reports Last Patient Last Visit in Pivotal Phase 3 Trial of Accordion Pill™ Carbidopa/Levodopa for the Treatment of Advanced Parkinson's Disease Patients  Yahoo FinanceCompany on track to report top-line data in July/August time frame JERUSALEM , April 30, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or ...
• Intec Pharma Announces Results from Earlier Phase 2 Clinical Trial of Accordion Pill-Carbidopa/Levodopa in Advanced Parkinson's Disease Patients Published in Parkinsonism and Related Disorders - P&T Community June 25, 2019 Intec Pharma Announces Results from Earlier Phase 2 Clinical Trial of Accordion Pill-Carbidopa/Levodopa in Advanced Parkinson's Disease Patients Published in Parkinsonism and Related Disorders  P&T CommunityJERUSALEM, June 25, 2019 /PRNewswire/ --- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that results from an earlier ...
• Intec Pharma Reports Last Patient Last Visit in Pivotal Phase 3 Trial of Accordion Pill™ Carbidopa/Levodopa for the Treatment of Advanced Parkinson's Disease Patients - BioSpace April 30, 2019 Intec Pharma Reports Last Patient Last Visit in Pivotal Phase 3 Trial of Accordion Pill™ Carbidopa/Levodopa for the Treatment of Advanced Parkinson's Disease Patients  BioSpacePublished: Apr 30, 2019. Company on track to report top-line data in July/August time frame. JERUSALEM, April 30, 2019 /PRNewswire/ -- Intec Pharma Ltd.
• Intec Pharma Announces Results from Earlier Phase 2 Clinical Trial of Accordion Pill-Carbidopa/Levodopa in Advanced Parkinson's Disease Patients Published in Parkinsonism and Related Disorders - Yahoo Finance June 25, 2019 Intec Pharma Announces Results from Earlier Phase 2 Clinical Trial of Accordion Pill-Carbidopa/Levodopa in Advanced Parkinson's Disease Patients Published in Parkinsonism and Related Disorders  Yahoo FinanceAccordion Pill demonstrated more stable levodopa concentrations and significantly reduced OFF time in Parkinson's disease patients JERUSALEM , June 25, ...
• Intec Pharma Highlights Potential of Accordion Pill® Oral Drug Delivery Platform in Two Posters at International Congress of Parkinson's and Movement Disorder Society September 25, 2019 JERUSALEM, Sept. 25, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that two posters highlighting data from the Company's Phase 3 clinical development program for the Accordion Pill® Carbidopa/Levodopa (AP-CD/LD), were presented yesterday...
• Intec Pharma to Present Two Posters at International Congress of Parkinson's and Movement Disorder Society September 16, 2019 JERUSALEM, Sept. 16, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that two posters in support of the Company's Phase 3 clinical development program for the Accordion Pill™ Carbidopa/Levodopa (AP-CD/LD), will be presented at the upcoming...
• Intec Pharma's Accordion Pill for Parkinson's shows positive action in mid-stage study June 25, 2019 Results from an open-label two-way crossover Phase 2 clinical trial evaluating Intec Pharma's (NASDAQ:NTEC) Accordion Pill - Carbidopa/Levodopa (AP-CD/LD) in Parkinson's disease (PD) patients ...
• Intec Pharma Announces Results from Earlier Phase 2 Clinical Trial of Accordion Pill-Carbidopa/Levodopa in Advanced Parkinson's Disease Patients Published in Parkinsonism and Related Disorders - BioSpace June 25, 2019 Intec Pharma Announces Results from Earlier Phase 2 Clinical Trial of Accordion Pill-Carbidopa/Levodopa in Advanced Parkinson's Disease Patients Published in Parkinsonism and Related Disorders  BioSpacePublished: Jun 25, 2019. Accordion Pill demonstrated more stable levodopa concentrations and significantly reduced OFF time in Parkinson's disease patients.
• Intec Pharma Highlights Potential of Accordion Pill® Oral Drug Delivery Platform in Two Posters at International Congress of Parkinson's and Movement Disorder Society - Yahoo Finance September 25, 2019 Intec Pharma Highlights Potential of Accordion Pill® Oral Drug Delivery Platform in Two Posters at International Congress of Parkinson's and Movement Disorder Society  Yahoo FinanceJERUSALEM, Sept. 25, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NTEC) ("Intec" or "the Company") today announces that two posters highlighting data from the ...
• Intec Pharma Reports First Quarter 2019 Financial Results and Corporate Update - Yahoo Finance May 7, 2019 Intec Pharma Reports First Quarter 2019 Financial Results and Corporate Update  Yahoo FinanceJERUSALEM, May 7, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NTEC) ("Intec" or "the Company") today announces financial results for the three months ended ...
• Intec Pharma Announces Results From Pharmacokinetic Study of AP-CD/LD 50/500 mg Dosed Three Times Daily Were Presented at the XXIV World Congress on Parkinson's Disease and Related Disorders June 19, 2019 JERUSALEM, June 19, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announced that results from a pharmacokinetics (PK) study of the Accordion Pill™-Carbidopa/Levodopa (AP-CD/LD) 50/500 mg dosed three times per day (TID) were highlighted yesterday in ...
• Intec Pharma Reports Second Quarter 2019 Financial Results and Business Update - Yahoo Finance August 9, 2019 Intec Pharma Reports Second Quarter 2019 Financial Results and Business Update  Yahoo FinanceJERUSALEM, Aug. 9, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NTEC) ("Intec" or "the Company") today announces financial results for the three and six months ...
• Intec Pharma Granted European Patent - Yahoo Finance May 20, 2019 Intec Pharma Granted European Patent  Yahoo FinanceJERUSALEM, May 20, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NTEC) ("Intec" or "the Company") today announces that the European Patent Office has granted ...
• Intec Pharma to Present Two Posters at International Congress of Parkinson's and Movement Disorder Society - Yahoo Finance September 16, 2019 Intec Pharma to Present Two Posters at International Congress of Parkinson's and Movement Disorder Society  Yahoo FinanceJERUSALEM, Sept. 16, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NTEC) ("Intec" or "the Company") today announces that two posters in support of the ...
• Intec Pharma Reports Second Quarter 2019 Financial Results and Business Update - P&T Community August 9, 2019 Intec Pharma Reports Second Quarter 2019 Financial Results and Business Update  P&T CommunityJERUSALEM, Aug. 9, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces financial results for the three and ...
• Intec Pharma Reports First Quarter 2019 Financial Results and Corporate Update - P&T Community May 7, 2019 Intec Pharma Reports First Quarter 2019 Financial Results and Corporate Update  P&T CommunityJERUSALEM, May 7, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces financial results for the three ...
• Intec Pharma Reports Second Quarter 2019 Financial Results and Business Update - BioSpace August 9, 2019 Intec Pharma Reports Second Quarter 2019 Financial Results and Business Update  BioSpacePublished: Aug 09, 2019. JERUSALEM, Aug. 9, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces financial ...
• Intec Pharma Highlights Potential of Accordion Pill® Oral Drug Delivery Platform in Two Posters at International Congress of Parkinson's and Movement Disorder Society - BioSpace September 25, 2019 Intec Pharma Highlights Potential of Accordion Pill® Oral Drug Delivery Platform in Two Posters at International Congress of Parkinson's and Movement Disorder Society  BioSpaceJERUSALEM, Sept. 25, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that two posters highlighting ...